A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Clinical trial NCT03694522 · COMPLETED
Trial details
- NCT number
- NCT03694522
- Sponsor
- Five Prime Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-09-14
- Primary completion
- 2020-09-23
- Enrollment
- 155
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.